In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) closed at $25.29 down -4.71% from its previous closing price of $26.54. In other words, the price has decreased by -$4.71 from its previous closing price. On the day, 1.84 million shares were traded. TNXP stock price reached its highest trading level at $27.2699 during the session, while it also had its lowest trading level at $25.1281.
Ratios:
For a deeper understanding of Tonix Pharmaceuticals Holding Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4. ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 21 ’25 when Taylor Carolyn E. bought 418 shares for $36.03 per share. The transaction valued at 15,061 led to the insider holds 418 shares of the business.
Treco James bought 250 shares of TNXP for $9,000 on Aug 20 ’25. The Director now owns 250 shares after completing the transaction at $36.00 per share. On May 15 ’25, another insider, LEDERMAN SETH, who serves as the Chief Executive Officer of the company, bought 4,000 shares for $21.55 each. As a result, the insider paid 86,200 and bolstered with 4,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 221689616 and an Enterprise Value of 96850512. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.55 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 9.852 whereas that against EBITDA is -1.212.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.92, which has changed by 0.58062506 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $130.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -37.48%, while the 200-Day Moving Average is calculated to be -9.86%.
Shares Statistics:
For the past three months, TNXP has traded an average of 1.37M shares per day and 1084570 over the past ten days. A total of 8.77M shares are outstanding, with a floating share count of 8.76M. Insiders hold about 0.08% of the company’s shares, while institutions hold 15.97% stake in the company. Shares short for TNXP as of 1755216000 were 1347517 with a Short Ratio of 0.99, compared to 1752537600 on 1188503. Therefore, it implies a Short% of Shares Outstanding of 1347517 and a Short% of Float of 15.370000000000001.
Earnings Estimates
The market rating for Tonix Pharmaceuticals Holding Corp (TNXP) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$3.05, with high estimates of -$3.05 and low estimates of -$3.05.
Analysts are recommending an EPS of between -$10.3 and -$10.3 for the fiscal current year, implying an average EPS of -$10.3. EPS for the following year is -$4.5, with 1.0 analysts recommending between -$4.5 and -$4.5.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $2.1M this quarter.It ranges from a high estimate of $2.1M to a low estimate of $2.1M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.82MFor the next quarter, 1 analysts are estimating revenue of $2.2M. There is a high estimate of $2.2M for the next quarter, whereas the lowest estimate is $2.2M.
A total of 1 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $8.7M, while the lowest revenue estimate was $8.7M, resulting in an average revenue estimate of $8.7M. In the same quarter a year ago, actual revenue was $10.09MBased on 3 analysts’ estimates, the company’s revenue will be $94.17M in the next fiscal year. The high estimate is $203.5M and the low estimate is $31.3M.